alexa
Reach Us +44-1753-390542
Editor - Muthukumar Gunasekaran | University of Maryland, Balti | 26737
ISSN: 0974-8369

Biology and Medicine
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Muthukumar Gunasekaran

Muthukumar Gunasekaran Muthukumar Gunasekaran
Research Associate, Department of Surgery, University of Maryland, Baltimore, Maryland, USA
Biography

I am a transplant immunologist who has made significant contributions to our understanding the role of immune response to mismatched HLA and tissue restricted self-antigens in inducing acute and chronic rejection following solid organ transplantation. Recent findings of my work demonstrated the role of exosomes in allograft rejection in human lung and heart transplantation. I was the first to report that exosomes derived from lung transplant recipients with acute and chronic rejections, but not those derived from stable LTxR, show surface expression of donor mismatched HLA and lung associated antigens, as well as immune regulatory miRNA. This clinically relevant study was published in the American Journal of Transplantation and appeared as a highlighted article in ASTS (American Society of Transplant Surgeons) as Brief News. I have received a Young Investigator Award by American Transplant Congress and the Scholar award by the American society for histocompatibility and immunogenetics for my study concerning the role of exosomes in lung transplant rejections. Currently I am working as Research Associate at Dr. Sunjay Kaushal lab in the University of Maryland Baltimore (UMB). Our laboratory mainly focuses on the application of stem cell transplantation based therapies for children with congenital heart disease. My study focuses on therapeutic application of neonatal Cardiac Progenitor Cells (nCPCs) in myocardial infarction. Our laboratory data provides evidence that these transplanted stem cells trigger a robust remodeling process in the infarcted myocardium by enhancing neovascularization through exosomes and paracrine factors. We have also shown that although transplanted nCPCs increase cardiac regeneration, immune rejections are the major complications limiting their therapeutic applications. Currently, my work focuses on studying the immune response to transplanted nCPCs and understanding how nCPCs and exosomes evade immune response to increases cardiac regeneration potential. Further, I propose that nCPCs administered with the immune suppressive regimen, cyclosporine A, would have enhanced therapeutic application for myocardial infarction. Recently we received an IND from the FDA to start the first clinical trial based on stem cell therapies in congenital heart disease patients.

Research Interest

My study focuses on therapeutic application of neonatal Cardiac Progenitor Cells (nCPCs) in myocardial infarction. Our laboratory data provides evidence that these transplanted stem cells trigger a robust remodeling process in the infarcted myocardium by enhancing neovascularization through exosomes and paracrine factors. We have also shown that although transplanted nCPCs increase cardiac regeneration, immune rejections are the major complications limiting their therapeutic applications. Currently, my work focuses on studying the immune response to transplanted nCPCs and understanding how nCPCs and exosomes evade immune response to increases cardiac regeneration potential. Further, I propose that nCPCs administered with the immune suppressive regimen, cyclosporine A, would have enhanced therapeutic application for myocardial infarction. Recently we received an IND from the FDA to start the first clinical trial based on stem cell therapies in congenital heart disease patients.

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2019-20
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri and Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

ankara escort

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

pendik escort

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2019 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version